Last Update 26 Jun 26
Fair value Decreased 14%APOTEA: Share Program Reforms Will Support Higher Future Profitability
Analysts have trimmed their Apotea price target from SEK 105 to SEK 90, citing updated assumptions that combine slightly lower revenue growth and a higher discount rate with expectations for a higher profit margin and a lower future P/E multiple.
What’s in the News for Apotea
- At the Annual General Meeting on May 26, 2026, Apotea shareholders approved amendments to the articles of association that introduce two new share classes: D shares and S shares. [Key Developments]
- D shares and S shares are set up as convertible and redeemable share classes. Each carries one tenth of a vote and no dividend rights under the updated articles. [Key Developments]
- The board received authorization to issue up to 1,000,000 D shares and to repurchase and transfer these D shares to participants in Apotea’s D Share Program 2026 at market value. [Key Developments]
- The board was also authorized to issue up to 1,050,000 S shares and to repurchase these S shares, creating additional flexibility in Apotea’s share structure. [Key Developments]
- Apotea’s board gained approval to transfer up to 800,000 ordinary shares free of charge under the Performance Share Program 2026 and up to 250,000 ordinary shares on Nasdaq Stockholm to cover program costs. [Key Developments]
Valuation Changes for Apotea
- Fair Value: The SEK fair value estimate has been reduced from SEK 105 to SEK 90.
- Discount Rate: The discount rate assumption has risen slightly from 5.13% to 5.34%.
- Revenue Growth: The long term SEK revenue growth assumption has been trimmed from 13.61% to 12.33%.
- Net Profit Margin: The assumed net profit margin has been raised from 3.96% to 4.48%.
- Future P/E: The future P/E multiple assumption has been lowered from 30.88x to 23.30x.
Catalysts
About Apotea
Apotea operates a Swedish online pharmacy platform that sells prescription medicines, OTC products and traded goods.
What are the underlying business or industry changes driving this perspective?
- Growing customer appetite for buying prescription medicines online, reflected in 13.6% Rx sales growth in Q3, gives Apotea a larger addressable market where higher Rx volumes can support revenue and help spread fixed costs, which can improve earnings over time.
- The new Varberg warehouse, currently at a fraction of its indicated 50,000 orders per day capacity, provides operational headroom so that rising order volumes can be absorbed with limited incremental CapEx, which can support EBIT margins as depreciation is matched by higher sales.
- Same day deliveries on Sweden's West Coast build on the shift toward fast, home based e commerce fulfillment and can support higher customer retention and order frequency, which is relevant for sustaining revenue and potentially supporting gross profit per customer.
- Ongoing efficiency work in both Morgongåva and Varberg, including tighter cost control and planned use of technology and AI, is aimed at keeping personnel and logistics costs in check as volumes rise, which can support net margins and operating cash flow.
- Emission free deliveries through an electrified delivery chain, together with recognition as the strongest pharmacy brand in Sweden, can strengthen Apotea's position with environmentally conscious consumers and brand loyal customers, which matters for long term revenue stability and pricing power that can support EBIT.
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Apotea's revenue will grow by 12.3% annually over the next 3 years.
- Analysts assume that profit margins will increase from 3.2% today to 4.5% in 3 years time.
- Analysts expect earnings to reach SEK 469.6 million (and earnings per share of SEK 3.98) by about June 2029, up from SEK 236.3 million today. The analysts are largely in agreement about this estimate.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 23.3x on those 2029 earnings, down from 33.1x today. This future PE is lower than the current PE for the SE Consumer Retailing industry at 28.1x.
- Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 5.34%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?
- The Varberg warehouse is currently running at about 10,000 orders a day against an indicated capacity of 50,000. The fixed assets of SEK 380 million will be depreciated over roughly 5 years. If order volumes do not scale as intended or ramp up more slowly, underutilised capacity and higher depreciation could weigh on EBIT margins and earnings.
- Rx currently grows faster than OTC and traded goods, and management expects Rx to expand further as a share of the mix. If the lower margin profile of Rx drags on overall gross margin more than expected, revenue growth could be accompanied by pressure on gross margin and net margins.
- The company has recently completed a large investment in Varberg and is considering additional profitable investments. If future capital allocation decisions do not generate returns in line with the current 34.4% return on capital employed, this could dilute returns on capital and constrain earnings growth.
- New delivery regulations and potential increases in freight costs may not materially affect the business today. However, if long term shipping and regulatory changes encourage customers to switch to peers with physical store networks or materially raise delivery costs, this could affect revenue growth and operating margins.
- The model relies on high inventory turnover and efficient logistics across both Morgongåva and Varberg. If inventory optimisation between warehouses takes longer than expected or Rx demand normalises while staffing and external consultants remain elevated, working capital needs and personnel costs could pressure operating cash flow and net margins.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of SEK90.0 for Apotea based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of SEK100.0, and the most bearish reporting a price target of just SEK80.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be SEK10.5 billion, earnings will come to SEK469.6 million, and it would be trading on a PE ratio of 23.3x, assuming you use a discount rate of 5.3%.
- Given the current share price of SEK75.05, the analyst price target of SEK90.0 is 16.6% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Apotea?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
